Headquartered in Cambridge, MA Fiscal year ends December NASDAQ: IMRX immuneering.com
Immuneering Corporation is a late-stage clinical oncology company focused on developing Deep Cyclic Inhibitors (DCIs), a new category of cancer medicines designed to improve overall survival by shrinking tumors durably with less resistance, preserving body mass by countering cachexia, and minimizing side effects. The company's lead product candidate, atebimetinib, is an oral, once-daily Deep Cyclic Inhibitor of MEK targeting RAS-, RAF-, and other MAPK-driven cancers. Immuneering is conducting a global randomized pivotal Phase 3 trial (MAPKeeper 301) evaluating atebimetinib in combination with chemotherapy in first-line metastatic pancreatic cancer. The development pipeline also includes combination opportunities with immunotherapy agents such as anti-PD-1 in non-small cell lung cancer, as well as preclinical-stage DCI programs. The company is pre-revenue and trades on Nasdaq under the ticker IMRX. Updated
Analyst sentiment across three small-cap biotechs has turned notably positive, with fresh coverage initiations and maintained Buy-equivalent ratings from institutional research desks ahead of 2026 clinical catalysts. All three names carry verified…
With the third quarter in full swing, the bulls have not lost their grip on equities. The market momentum isn’t likely to run out of steam anytime soon, according to UBS strategist Vincent…
Immuneering Corporation is a late-stage clinical oncology company focused on developing Deep Cyclic Inhibitors (DCIs), a new category of cancer medicines designed to improve overall survival by shrinking tumors durably with less resistance, preserving body mass by countering cachexia, and minimizing side effects.
The Wall Street consensus 12-month price target for IMRX is $17.17.
